Industry publication covers Fibronostics acquisition
Intelligence360 reported on the Stone Clinical Laboratories transaction and outlined how the acquisition could support Fibronostics’ U.S. laboratory operations and liver-diagnostics strategy.
A selection of verifiable announcements, partnerships, and milestones involving STONE Diagnostics and Stone Clinical Laboratories, linked to the original publishers.
Coverage is arranged newest first. Each item links to its original source, including its publication date and publisher.
Intelligence360 reported on the Stone Clinical Laboratories transaction and outlined how the acquisition could support Fibronostics’ U.S. laboratory operations and liver-diagnostics strategy.
Fibronostics announced the acquisition of Stone Clinical Laboratories, describing an expansion of its U.S. laboratory capabilities and work in liver and metabolic disease diagnostics.
The announcement outlines a collaboration to provide preventive-care laboratory testing services to physicians and patients in the Altus ACE network.
The companies announced a partnership supporting physician access to Fibronostics’ LIVERFASt liver-health assessment through STONE’s laboratory service platform.
A services and co-marketing partnership sought to widen the availability of COVID-19 testing in laboratory and high-volume screening environments.
The laboratory announced an agreement focused on revenue-cycle management, payment collection, and reimbursement administration for laboratory services.
The company announced a collaboration intended to expand COVID-19 testing capacity and access in Louisiana during the pandemic.
A company-hosted announcement described work to bring testing capabilities to healthcare and community settings in Mississippi.
Stone reported accreditation through the College of American Pathologists following an on-site inspection of its laboratory operations.
Archive compiled October 2026. These links point to source material, primarily company or partner announcements. “Newswire” and “PR Newswire” are distribution/publishing platforms, not an indication of independent editorial endorsement.
Visit STONE Diagnostics’ own news and information pages for updates after this archive was prepared.